These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 3260537

  • 1. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA.
    Cancer Res; 1988 Aug 01; 48(15):4409-16. PubMed ID: 3260537
    [Abstract] [Full Text] [Related]

  • 2. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA.
    Cancer Res; 1988 Oct 15; 48(20):5864-7. PubMed ID: 3139285
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF.
    Cancer Res; 1990 Oct 01; 50(19):6302-10. PubMed ID: 2205379
    [Abstract] [Full Text] [Related]

  • 5. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S.
    Cancer Res; 1990 Nov 15; 50(22):7343-50. PubMed ID: 2224862
    [Abstract] [Full Text] [Related]

  • 6. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 7. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
    McMannis JD, Fisher RI, Creekmore SP, Braun DP, Harris JE, Ellis TM.
    J Immunol; 1988 Feb 15; 140(4):1335-40. PubMed ID: 3257776
    [Abstract] [Full Text] [Related]

  • 8. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T, Farace F, Baume D, Charpentier F, Droz JP, Triebel F, Escudier B.
    J Biol Response Mod; 1990 Dec 15; 9(6):546-55. PubMed ID: 2074441
    [Abstract] [Full Text] [Related]

  • 9. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N, Ozaki A, Ishihara J, Sakurai M, Sasaki Y, Takahashi H, Sano T, Hoshi A.
    Gan To Kagaku Ryoho; 1986 Apr 15; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [Abstract] [Full Text] [Related]

  • 10. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA.
    Cancer Res; 1986 Feb 15; 46(2):676-83. PubMed ID: 3484431
    [Abstract] [Full Text] [Related]

  • 11. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG, Abraham SR, Owen-Schaub LB, Hemingway LL, Hemstreet GP, DeBault LE.
    Cancer Res; 1988 Apr 15; 48(8):2184-92. PubMed ID: 3258186
    [Abstract] [Full Text] [Related]

  • 12. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 15; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 13. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ.
    Cancer Res; 1988 Sep 01; 48(17):5007-10. PubMed ID: 3261630
    [Abstract] [Full Text] [Related]

  • 14. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C.
    Surgery; 1986 Aug 01; 100(2):262-72. PubMed ID: 3526604
    [Abstract] [Full Text] [Related]

  • 15. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT.
    N Engl J Med; 1985 Dec 05; 313(23):1485-92. PubMed ID: 3903508
    [Abstract] [Full Text] [Related]

  • 16. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC, Herberman RB.
    Cancer Res; 1988 Jun 15; 48(12):3461-9. PubMed ID: 3259468
    [Abstract] [Full Text] [Related]

  • 17. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM, Ussery D, Reintgen DS, Puleo CA, Djeu JY.
    Cancer Res; 1995 Nov 01; 55(21):4988-94. PubMed ID: 7585540
    [Abstract] [Full Text] [Related]

  • 18. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Cancer Res; 1986 Jun 01; 46(6):2784-92. PubMed ID: 3486038
    [Abstract] [Full Text] [Related]

  • 19. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
    Lamers HJ, Gratama JW, van Putten WL, Stoter G, Bolhuis RL.
    Cancer Res; 1991 May 01; 51(9):2324-8. PubMed ID: 2015597
    [Abstract] [Full Text] [Related]

  • 20. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ, Silver HK, Kong S.
    Cancer Res; 1990 Aug 15; 50(16):4906-10. PubMed ID: 2379154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.